The CSL Ltd (ASX: CSL) share price closed higher today, finishing 2.37% in the green at $262.62.
The gain comes despite nothing remarkable coming out of the biotech giant’s camp today.
However, the company’s shares jumped from the open, trading as high at $264.17 apiece and as low as $258.53 each during the day.
There’s been nothing price-sensitive out of CSL’s corner today. However, it appears that healthcare shares, on the whole, are strengthening this week.
The S&P/ASX 200 Health Care Index (XHJ) gained around 2% from the start of trade today, finishing 1.86% higher.
CSL is also on the rise this week, as illustrated by the chart below.
In a note that bodes well for CSL, analysts at Citi have pointed out potential growth in the blood plasma collection industry.
The broker reckons that CSL’s blood plasma collection volumes could normalise to pre-pandemic levels, which could have a positive impact on the company’s share price.
Currently, more than 87% of brokers covering CSL have it as a buy right now whereas just two firms have it as a hold, according to Bloomberg Intelligence. Indeed, there are no analysts urging clients to sell the company right now.
CSL is offering some donors incentives in a bid to increase volumes. At the same time, it was reported CSL upped its payment to US donors during the pandemic to entice people to keep their appointments. CSL is one of a handful of blood plasma collection vendors around the world.
Recently, on 10 March, the company advised that it had received clearance in the US for use of the Rika Plasma Donation System developed by Terumo Blood and Cell Technologies.
“CSL Plasma believes additional features of the new Rika system can enable the collection of more plasma, in shorter periods of time, supporting quality and safety, and ultimately better serving patients who rely on plasma-based therapies,” the company said in a statement.
Citi’s rating appears to recognise CSL’s efforts to drive its collection volumes higher.
CSL share price snapshot
In the last 12 months, the CSL share price has climbed almost 4% but is down almost 10% this year to date.
During the past month, things have turned around with the company’s shares gaining almost 6%.
CSL has a market capitalisation of more than $126 billion.
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
- Why CSL, Dicker Data, Elders, and Virtus Health shares are charging higher
- Leading brokers name 3 ASX shares to buy today
- ASX 200 (ASX:XJO) midday update: Elders jumps, Magellan and Zip tumble
- $20k invested in these ASX shares 10 years ago is now worth…
- The CSL (ASX:CSL) share price has struggled to gain traction in 2022. Does that make it cheap?
Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/AoLxY8K